Lyra Therapeutics Q2 net loss $15.6M; cash $116.2M after $46.7M placement

Lyra Therapeutics, Inc.

2023-Q2 EPS reported -$0.79 revenue$868,000

Cash and investments $116.2M at June 30, 2023, up from $82.7M at March 31, 2023.
Net loss $15.6M for Q2 2023 vs $14.4M in Q2 2022; R&D expense flat at $10.8M.
ENLIGHTEN I Phase 3 enrollment completion expected in weeks; data 1H 2024.
BEACON Phase 2 topline results for LYR-220 now expected September 2023.
Private placement closed May 31, 2023 yielded net proceeds of $46.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Lyra Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $15.6 million.

Period: the second quarter ended June 30, 2023
Net income: $15.6 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended June 30, 2023 was $15.6 million compared to $14.4 million for the same period in 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.